ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research
Shanghai, China (May 12, 2020) – Shanghai ChemPartner announced they have entered into a non-exclusive agreement with the Mount Sinai Health System (Mount Sinai) to assist in a trial production run of a component of the Mount Sinai COVID-19 serological assay that recently received Emergency Use Authorization from the U.S. Food and Drug Administration for use in Mount Sinai’s lab during the COVID-19 emergency declaration. The Assay enables Mount Sinai to test patient populations for the presence or absence of COVID-19 antibodies. “We are very excited about this opportunity with Mount Sinai,” said Wei Tang, CEO at ChemPartner. “ChemPartner is eager to do whatever we can to help the scientific community during this pandemic, and our experienced research teams are enthusiastic about this Assay and its potential for patients around the world.” “We’re continuing to advance the development of serologic testing for SARS-CoV-2 at Mount Sinai, and are forming collaborations, such as this with ChemPartner, to enable these important efforts,” said Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer for the Mount Sinai Health System. The assay currently authorized under the FDA EUA determines the presence of anti-COVID-19 antibodies and is not approved for detection of COVID-19 virus or any other virus or pathogen. For inquiries related to commercial licensing of the Mount Sinai serological assay, please visit www.mountsinai.org/covidantibodytest. About ChemPartner Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical Development, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC. Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. About the Mount Sinai Health System The Mount Sinai Health System...ChemPartner and the Gladstone Institutes Announce COVID-19 Research Collaboration
SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020) – In a new collaboration, Chempartner Corporation (ChemPartner), the US arm of a leading pre-clinical contract research and development organization (CRO), is partnering with scientists at Gladstone Institutes, an independent biomedical research organization, to accelerate the discovery of novel therapeutics and diagnostics for the novel coronavirus, SAR-CoV-2 (COVID-19). The partnership will bring together leading academic researchers in the area of virology with the broad scope of resources available from a well-established and experienced CRO. The scientists at each organization will work in close partnership on a number of projects to quickly and efficiently advance research in this critical area in the hope of bringing new therapeutics and/or diagnostics to patients. “We find ourselves in an unprecedented situation today as the COVID-19 pandemic spreads and impacts lives across the globe,” said Wei Tang, PhD, chief executive officer, ChemPartner. “As a leading science-driven and technology-based CRO, we want to do our part to fight this disease. We are honored and excited to be partnering with such experienced researchers at Gladstone. We expect to quickly yield meaningful results.” The collaboration will take advantage of Gladstone’s ability to work with live virus and novel ex vivo assays, as well as unique access to COVID-19 patients’ samples. ChemPartner’s initiative will be led by the experienced researchers out of its South San Francisco Innovation Center but leverage resources in both the US and China. “Gladstone scientists have leapt to action to learn more about this virus, develop diagnostics, and discover therapeutic approaches,” said Gladstone President Deepak Srivastava, MD. “By building on our prior successes in transforming HIV treatment, and leveraging our partnerships, I believe we have the tools and knowledge in place to make a difference in this current pandemic.” About Gladstone Institutes To ensure our work...ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai
Shanghai, China (March 17, 2020) – Shanghai ChemPartner announced the opening of a new, state-of-the-art, 24,000 m2 laboratory facility in the Zhangjiang Hi-Tech Park in Shanghai, China. The building, operating as ChemPartner’s new Global Operation Center, houses approximately 700 employees and new laboratories for ChemPartner’s discovery chemistry, biology and pharmacology, and the DMPK and exploratory toxicology departments. It also has a nearly 2,000 m2, AAALAC accredited animal facility. “This facility demonstrates ChemPartner’s commitment to be an innovative, technology-driven CRO,” said Michael Hui, Chairman at ChemPartner. “We invested $35 million dollars into this new facility to make it a premiere drug discovery and development solution for our global clients.” Dr. Wei Tang, President at ChemPartner added, “All of us at ChemPartner are dedicated to research innovation to provide our biopharmaceutical clients with exceptional quality and timely results. Along with our Innovation Center in San Francisco, California, this new facility in Shanghai shows our dedication to technically and strategically accomplishing the research initiatives of our clients.” In addition to laboratory and scientific teams, the new Global Operations Center also houses ChemPartner’s administration, finance, and legal teams. As more and more pharmaceutical and biotech companies look for quality service providers, ChemPartner is uniquely positioned to not only be a CRO and CMO, but to be a reliable pharmaceutical alliance partner providing intellectual contributions and exceptional technical expertise. About ChemPartner Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical Development, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC. Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. --- FOR MORE INFORMATION Livia Legg, MS, Chief Commercial Officer...Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry
Shanghai, China (December 17, 2019) – Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China. Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and process chemistry. He is also widely published as an author or co-author of 34 peer-reviewed articles, 12 patents, and 29 books. Prior to joining ChemPartner, Dr. Li worked at Pfizer, BMS, and Revolution Medicines in oncology, antivirals, metabolic disease, CNS, anti-inflammatory, and dermatology, targeting enzymes, receptors, or ion channels. Dr. Li was also a professor at the University of San Francisco for four years, teaching organic and medicinal chemistry. He earned his Ph.D. from Indiana University and was a post-doctoral fellow at MIT. “Chemistry continues to be a major business area for ChemPartner, and we are investing in our facilities, capabilities, technology, and leadership,” said Dr. Wei Tang, CEO of ChemPartner. “We are thrilled for Dr. Li to join the ChemPartner Chemistry Leadership Team. His tenured industry experience and expertise in medicinal and process chemistry will be a valuable asset for both ChemPartner and our clients.” “Jack joins ChemPartner at a really exciting time” said Dr Sarah Lively, VP, Innovation and New Technologies based in ChemPartner’s South San Francisco Innovation Center. As we look to harness the full power of the many years ChemPartner has spent building world-class teams and infrastructure to support drug discovery, Jack will really be able to help lead the chemistry group in driving small molecule drug discovery programs for our clients and strategic partners. He will work closely with my team in the US as well as the team in China to both leverage the existing expertise as well as bridge in the new capabilities from the innovation...
Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”
Contract manufacturers play a significant role when it comes to manufacturing medical products. By partnering with the right CM, a medical device manufacturer can save plenty of time and overhead costs. Life sciences companies need CMOs due to the potential rise in the number of products that are going through preclinical and clinical development and are relying on contract manufacturing to execute their unique requirements while cutting costs. The contract manufacturing organizations are looking at new technologies to boost economies of scale, improve manufacturing productivity, and overall efficiency. They are currently using AI to generate novel drug candidates, understanding disease mechanisms, as well as aggregating and synthesizing information. Big data analytics also plays a crucial role in the contract manufacturing industry where organizations are widely adopting data integration, master data management, and visualization tools to determine demand forecasts, production planning, inventory optimization, and operation planning data. While pharma companies refocus their core strengths and assets, CDMOs are playing a crucial role in providing added facilities to mitigate the risk of supply shortages by supplying multisite strategies and backup capacities. To steer CIOs in the right direction while choosing the right contract manufacturing services provider, an esteemed panel of CEOs, CIOs, VCs and analysts in coordination with Pharma Tech Outlook’s editorial board have put together a list of the leading CMOs in the industry. The vendors featured in the edition have exhibited their capabilities in providing exceptional services along with a host of innovative technologies. We present to you the “Top 10 CMOs - 2019.” ChemPartner A True Pharmaceutical Alliance Partner The timeline between nominating a compound as a New Clinical Entity (NCE) and ultimately marketing the drug on a commercial scale has remained the same for decades—typically five to six years. However, in the biopharmaceutical marketplace, a company called ChemPartner—through...Dr. Teddy Yang appointed to Vice President and Head of Biologics Discovery at Shanghai ChemPartner
Shanghai, China(Mar 28, 2019) – Shanghai ChemPartner today announced the appointment of Teddy Yang, Ph.D. as the Vice President and Head of Biologics Discovery at the company headquarters in Shanghai, China. Dr. Yang has more than 20 years of experience in the pharmaceutical industry. He has previously worked in Genentech, Novartis Institute for Biomedical Research, and RuiYi Biopharmaceuticals before joining the Biologics Discovery team at ChemPartner in 2015. Dr. Yang has been a consistent leader of ChemPartner’s world-class biologics discovery operations and its staff of over 150 scientists. “I am proud of how the biologics discovery department at ChemPartner has grown, and I look forward to seeing Dr. Yang lead the company into the future,” said Dr. Wei Tang, CEO of ChemPartner. “Dr. Yang’s expertise and commitment to the scientific excellence will ensure a bright future for ChemPartner and our global biopharmaceutical clients.” “It is a pleasure to continue to serve ChemPartner and our clients in my new role as Head of Biologics Discovery. Our company is comprised of hardworking people dedicated to maintaining our reputation as a preeminent drug discovery and development research organization. I am excited to see what is ahead for the Biologics Discovery department and the company as a whole,” said Dr. Yang. As one of the leading Biologics Discovery CROs in the world, ChemPartner provides a comprehensive service portfolio from conceptual biologics design to the pre-clinical (IND filing) stage including antibody discovery, antibody drug conjugate (ADC) platform, analytics, and protein and antibody production. Our team of scientists has the full spectrum of specialty areas and extensive experience in biologics. In close collaboration with colleagues in pharmacology and DMPK, the Biologics Discovery department applies cutting-edge technologies and is dedicated to helping clients discover and develop tomorrow’s therapeutics. About ChemPartner Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics,...ChemPartner Will Participate in BIO-Europe Spring in Vienna, Austria in March 2019
Shanghai, China (March X, 2019) – March 25-27, 2019, ChemPartner will attend the 13th Annual International Partnering Conference BIO-Europe Spring in Vienna, Austria. With nearly 1,500 companies from 55 countries around the world, BIO-Europe is set to be a premier venue to engage with global life science partners. To schedule a meeting with ChemPartner, you may do so via BIO-Europe’s online partnership platform at: https://ebdgroup.knect365.com/bioeurope-spring/. For more information, please contact: Ron Shevock – Interim Head, ChemPartner Europe ApS Phone: +45 5363 3747 E-mail: rshevock@chempartner.com About ChemPartner Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical Development, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC. Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. --- FOR MORE INFORMATION Livia Legg, MS, Chief Commercial Officer news@chempartner.com
ChemPartner will be at the Boulder Peptide Symposium 2018
ChemPartner, a leader in Peptide Synthesis and Development, will be at the Boulder Peptide Symposium, Sept. 24-27, 2018 in Boulder, Colorado. The program was organized by Dr. Yvonne Angell, who is the Head of Peptide Operations at ChemPartner. There are 43 speakers, including a Showcase of emerging Peptide Companies, a CEO roundtable, a Peptide Analytics Workshop, and plenty of opportunities to network and learn about recent advancements in peptide research and therapeutics. ChemPartner will be presenting on Chemerin Analogs Selective for CMKLR1 and KISS1R Peptide Agonists for Prostate Cancer. More information about the conference: http://boulderpeptide.org